Haemonetics Corporation (HAE) 当前追踪市盈率 (P/E) 为 15.6, 前瞻市盈率为 12.2. 追踪盈利收益率为 6.39%, 前瞻盈利收益率 8.18%. PEG 0.35 (Peter Lynch 低估标准 ≤1.0). 格雷厄姆数为 $40.54.
本页证实的标准:
SharesGrow 综合评分： 77/100 其中 6/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | -32.0 | 0.07 | 2.47 | 1.96 | - |
| 2017 | -79.5 | 1.49 | 2.83 | 2.36 | - |
| 2018 | 84.7 | -0.32 | 5.13 | 4.27 | - |
| 2019 | 84.1 | 3.44 | 6.93 | 4.78 | - |
| 2020 | 66.0 | 1.61 | 8.60 | 5.11 | - |
| 2021 | 70.8 | 17.82 | 7.69 | 6.46 | - |
| 2022 | 74.4 | -1.62 | 4.31 | 3.25 | - |
| 2023 | 36.4 | 0.22 | 5.14 | 3.60 | - |
| 2024 | 36.6 | 16.60 | 4.48 | 3.28 | - |
| 2025 | 19.0 | 0.44 | 3.87 | 2.34 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2020 | $1.48 | $988.48M | $76.53M | 7.7% |
| 2021 | $1.55 | $870.46M | $79.47M | 9.1% |
| 2021 | $1.55 | $870.46M | $79.47M | 9.1% |
| 2022 | $0.84 | $993.2M | $43.38M | 4.4% |
| 2022 | $0.84 | $993.2M | $43.38M | 4.4% |
| 2023 | $2.24 | $1.17B | $115.4M | 9.9% |
| 2023 | $2.24 | $1.17B | $115.4M | 9.9% |
| 2024 | $2.29 | $1.31B | $117.56M | 9% |
| 2024 | $2.29 | $1.31B | $117.56M | 9% |
| 2025 | $3.31 | $1.36B | $167.68M | 12.3% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $4.95 | $4.93 – $4.98 | $1.33B | $1.32B – $1.34B | 8 |
| 2027 | $5.32 | $5.15 – $5.49 | $1.39B | $1.37B – $1.41B | 8 |
| 2028 | $5.93 | $5.52 – $6.17 | $1.49B | $1.49B – $1.49B | 5 |
| 2029 | $6.90 | $6.76 – $7.02 | $1.64B | $1.61B – $1.66B | 3 |
| 2030 | $7.66 | $7.50 – $7.80 | $1.76B | $1.73B – $1.78B | 3 |
